SrasV1, PascalFrancis, Corpus, bibRecord, 000533

Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide

Identifieur interne : 000533 ( PascalFrancis/Corpus ); précédent : 000532; suivant : 000534

Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide

Auteurs : MUSHENG BAO ; YI ZHANG ; MIN WAN ; LI DAI ; XIAOPING HU ; XIULI WU ; LI WANG ; PING DENG ; JUNZHI WANG ; JIANZHU CHEN ; YONGJUN LIU ; YONGLI YU ; LIYING WANG

Source :

Clinical immunology : (Orlando, Fla. Print) [ 1521-6616 ] ; 2006.

RBID : Pascal:06-0171874

Descripteurs français

Pascal (Inist)
- Syndrome respiratoire aigu sévère, Coronavirus, Immunité, Interféron gamma, Séquence riche GC, Séquence nucléotide, Oligodésoxyribonucléotide, Mononucléaire, Lymphocyte B, Cellule NK.

English descriptors

KwdEn :
- B-Lymphocyte, Coronavirus, GC rich sequence, Gamma interferon, Immunity, Mononuclear cell, Natural killer cell, Nucleotide sequence, Oligodeoxyribonucleotide, Severe acute respiratory syndrome.

Abstract

To develop CpG oligodeoxynucleotides (CpG ODNs) based therapy for prevention and treatment of severe acute respiratory syndrome (SARS), we selected a novel CpG ODN (BW001), which displays B-type CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3', and tested for its anti-SARS-CoV activity. We found that the supematants of human PBMCs stimulated by BW001 significantly protected Vero cells from SARS-CoV infection. BW001 could stimulate human PBMCs and pDCs to secrete high level of IFN-α and promote human PBMCs and B cells to proliferate. Furthermore, we demonstrated that BW001 could activate CD19⁺ B cells and CD56⁺ NK cells in human PBMCs. In addition, BW001 could enhance NK cytotoxicity and IFN-γ secretion in human PBMCs. Together, BW001 represents a novel type of CpG ODN and may have potential for the development of treatment and prevention for SARS as well as other viral associated diseases.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1521-6616`
A02	`01`			`@0 CLIIFY`
A03		`1`		`@0 Clin. immunol. : (Orlando, Fla., Print)`
A05				`@2 118`
A06				`@2 2-3`
A08	`01`	`1`	`ENG`	`@1 Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide`
A11	`01`	`1`		`@1 MUSHENG BAO`
A11	`02`	`1`		`@1 YI ZHANG`
A11	`03`	`1`		`@1 MIN WAN`
A11	`04`	`1`		`@1 LI DAI`
A11	`05`	`1`		`@1 XIAOPING HU`
A11	`06`	`1`		`@1 XIULI WU`
A11	`07`	`1`		`@1 LI WANG`
A11	`08`	`1`		`@1 PING DENG`
A11	`09`	`1`		`@1 JUNZHI WANG`
A11	`10`	`1`		`@1 JIANZHU CHEN`
A11	`11`	`1`		`@1 YONGJUN LIU`
A11	`12`	`1`		`@1 YONGLI YU`
A11	`13`	`1`		`@1 LIYING WANG`
A14	`01`			`@1 Department of Molecular Biology, College of Basic Medicine, Jilin University @2 Changchun 130021 @3 CHN @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 13 aut.`
A14	`02`			`@1 National Institute for the Control of Pharmaceutical and Biological Products @2 Beijing 100050 @3 CHN @Z 2 aut. @Z 9 aut.`
A14	`03`			`@1 Department of Immunology, College of Basic Medicine, Jilin University @2 Changchun 130021 @3 CHN @Z 7 aut. @Z 12 aut.`
A14	`04`			`@1 The Blood Center of Jilin Province @2 Changchun 130033 @3 CHN @Z 8 aut.`
A14	`05`			`@1 Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology @2 Cambridge, MA 02139 @3 USA @Z 10 aut.`
A14	`06`			`@1 Department of Immunology and Center for Cancer Immunology Research, University of Texas, M.D. Anderson Cancer Center @2 Houston, TX 77030 @3 USA @Z 11 aut.`
A20				`@1 180-187`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 15461 @5 354000153419030080`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 29 ref.`
A47	`01`	`1`		`@0 06-0171874`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Clinical immunology : (Orlando, Fla. Print)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 To develop CpG oligodeoxynucleotides (CpG ODNs) based therapy for prevention and treatment of severe acute respiratory syndrome (SARS), we selected a novel CpG ODN (BW001), which displays B-type CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3', and tested for its anti-SARS-CoV activity. We found that the supematants of human PBMCs stimulated by BW001 significantly protected Vero cells from SARS-CoV infection. BW001 could stimulate human PBMCs and pDCs to secrete high level of IFN-α and promote human PBMCs and B cells to proliferate. Furthermore, we demonstrated that BW001 could activate CD19⁺ B cells and CD56⁺ NK cells in human PBMCs. In addition, BW001 could enhance NK cytotoxicity and IFN-γ secretion in human PBMCs. Together, BW001 represents a novel type of CpG ODN and may have potential for the development of treatment and prevention for SARS as well as other viral associated diseases.
C02	`01`	`X`		`@0 002B06`
C02	`02`	`X`		`@0 002A06`
C03	`01`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 02`
C03	`02`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 02`
C03	`02`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 02`
C03	`03`	`X`	`FRE`	`@0 Immunité @5 03`
C03	`03`	`X`	`ENG`	`@0 Immunity @5 03`
C03	`03`	`X`	`SPA`	`@0 Inmunidad @5 03`
C03	`04`	`X`	`FRE`	`@0 Interféron gamma @5 04`
C03	`04`	`X`	`ENG`	`@0 Gamma interferon @5 04`
C03	`04`	`X`	`SPA`	`@0 Interferón gamma @5 04`
C03	`05`	`X`	`FRE`	`@0 Séquence riche GC @5 05`
C03	`05`	`X`	`ENG`	`@0 GC rich sequence @5 05`
C03	`05`	`X`	`SPA`	`@0 Secuencia rica GC @5 05`
C03	`06`	`X`	`FRE`	`@0 Séquence nucléotide @5 06`
C03	`06`	`X`	`ENG`	`@0 Nucleotide sequence @5 06`
C03	`06`	`X`	`SPA`	`@0 Secuencia nucleótido @5 06`
C03	`07`	`X`	`FRE`	`@0 Oligodésoxyribonucléotide @5 08`
C03	`07`	`X`	`ENG`	`@0 Oligodeoxyribonucleotide @5 08`
C03	`07`	`X`	`SPA`	`@0 Oligodesoxirribonucleótido @5 08`
C03	`08`	`X`	`FRE`	`@0 Mononucléaire @5 11`
C03	`08`	`X`	`ENG`	`@0 Mononuclear cell @5 11`
C03	`08`	`X`	`SPA`	`@0 Mononuclear @5 11`
C03	`09`	`X`	`FRE`	`@0 Lymphocyte B @5 12`
C03	`09`	`X`	`ENG`	`@0 B-Lymphocyte @5 12 @6 «B»-Lymphocyte`
C03	`09`	`X`	`SPA`	`@0 Linfocito B @5 12`
C03	`10`	`X`	`FRE`	`@0 Cellule NK @5 17`
C03	`10`	`X`	`ENG`	`@0 Natural killer cell @5 17`
C03	`10`	`X`	`SPA`	`@0 Célula NK @5 17`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`04`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`05`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`05`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`05`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`06`	`X`	`FRE`	`@0 Immunologie @5 37`
C07	`06`	`X`	`ENG`	`@0 Immunology @5 37`
C07	`06`	`X`	`SPA`	`@0 Inmunología @5 37`
C07	`07`	`X`	`FRE`	`@0 Immunopathologie @5 38`
C07	`07`	`X`	`ENG`	`@0 Immunopathology @5 38`
C07	`07`	`X`	`SPA`	`@0 Inmunopatología @5 38`
C07	`08`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 39`
C07	`08`	`X`	`ENG`	`@0 Respiratory disease @5 39`
C07	`08`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 39`
C07	`09`	`X`	`FRE`	`@0 Poumon pathologie @5 40`
C07	`09`	`X`	`ENG`	`@0 Lung disease @5 40`
C07	`09`	`X`	`SPA`	`@0 Pulmón patología @5 40`
N21				`@1 107`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0171874 INIST
ET :	Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide
AU :	MUSHENG BAO; YI ZHANG; MIN WAN; LI DAI; XIAOPING HU; XIULI WU; LI WANG; PING DENG; JUNZHI WANG; JIANZHU CHEN; YONGJUN LIU; YONGLI YU; LIYING WANG
AF :	Department of Molecular Biology, College of Basic Medicine, Jilin University/Changchun 130021/Chine (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 13 aut.); National Institute for the Control of Pharmaceutical and Biological Products/Beijing 100050/Chine (2 aut., 9 aut.); Department of Immunology, College of Basic Medicine, Jilin University/Changchun 130021/Chine (7 aut., 12 aut.); The Blood Center of Jilin Province/Changchun 130033/Chine (8 aut.); Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology/Cambridge, MA 02139/Etats-Unis (10 aut.); Department of Immunology and Center for Cancer Immunology Research, University of Texas, M.D. Anderson Cancer Center/Houston, TX 77030/Etats-Unis (11 aut.)
DT :	Publication en série; Niveau analytique
SO :	Clinical immunology : (Orlando, Fla. Print); ISSN 1521-6616; Coden CLIIFY; Etats-Unis; Da. 2006; Vol. 118; No. 2-3; Pp. 180-187; Bibl. 29 ref.
LA :	Anglais
EA :	To develop CpG oligodeoxynucleotides (CpG ODNs) based therapy for prevention and treatment of severe acute respiratory syndrome (SARS), we selected a novel CpG ODN (BW001), which displays B-type CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3', and tested for its anti-SARS-CoV activity. We found that the supematants of human PBMCs stimulated by BW001 significantly protected Vero cells from SARS-CoV infection. BW001 could stimulate human PBMCs and pDCs to secrete high level of IFN-α and promote human PBMCs and B cells to proliferate. Furthermore, we demonstrated that BW001 could activate CD19⁺ B cells and CD56⁺ NK cells in human PBMCs. In addition, BW001 could enhance NK cytotoxicity and IFN-γ secretion in human PBMCs. Together, BW001 represents a novel type of CpG ODN and may have potential for the development of treatment and prevention for SARS as well as other viral associated diseases.
CC :	002B06; 002A06
FD :	Syndrome respiratoire aigu sévère; Coronavirus; Immunité; Interféron gamma; Séquence riche GC; Séquence nucléotide; Oligodésoxyribonucléotide; Mononucléaire; Lymphocyte B; Cellule NK
FG :	Virose; Infection; Coronaviridae; Nidovirales; Virus; Immunologie; Immunopathologie; Appareil respiratoire pathologie; Poumon pathologie
ED :	Severe acute respiratory syndrome; Coronavirus; Immunity; Gamma interferon; GC rich sequence; Nucleotide sequence; Oligodeoxyribonucleotide; Mononuclear cell; B-Lymphocyte; Natural killer cell
EG :	Viral disease; Infection; Coronaviridae; Nidovirales; Virus; Immunology; Immunopathology; Respiratory disease; Lung disease
SD :	Síndrome respiratorio agudo severo; Coronavirus; Inmunidad; Interferón gamma; Secuencia rica GC; Secuencia nucleótido; Oligodesoxirribonucleótido; Mononuclear; Linfocito B; Célula NK
LO :	INIST-15461.354000153419030080
ID :	06-0171874

Links to Exploration step

Pascal:06-0171874

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide</title>
<author><name sortKey="Musheng Bao" sort="Musheng Bao" uniqKey="Musheng Bao" last="Musheng Bao">MUSHENG BAO</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Molecular Biology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yi Zhang" sort="Yi Zhang" uniqKey="Yi Zhang" last="Yi Zhang">YI ZHANG</name>
<affiliation><inist:fA14 i1="02"><s1>National Institute for the Control of Pharmaceutical and Biological Products</s1>
<s2>Beijing 100050</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Min Wan" sort="Min Wan" uniqKey="Min Wan" last="Min Wan">MIN WAN</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Molecular Biology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Li Dai" sort="Li Dai" uniqKey="Li Dai" last="Li Dai">LI DAI</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Molecular Biology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Xiaoping Hu" sort="Xiaoping Hu" uniqKey="Xiaoping Hu" last="Xiaoping Hu">XIAOPING HU</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Molecular Biology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Xiuli Wu" sort="Xiuli Wu" uniqKey="Xiuli Wu" last="Xiuli Wu">XIULI WU</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Molecular Biology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Li Wang" sort="Li Wang" uniqKey="Li Wang" last="Li Wang">LI WANG</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Immunology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>7 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ping Deng" sort="Ping Deng" uniqKey="Ping Deng" last="Ping Deng">PING DENG</name>
<affiliation><inist:fA14 i1="04"><s1>The Blood Center of Jilin Province</s1>
<s2>Changchun 130033</s2>
<s3>CHN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Junzhi Wang" sort="Junzhi Wang" uniqKey="Junzhi Wang" last="Junzhi Wang">JUNZHI WANG</name>
<affiliation><inist:fA14 i1="02"><s1>National Institute for the Control of Pharmaceutical and Biological Products</s1>
<s2>Beijing 100050</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jianzhu Chen" sort="Jianzhu Chen" uniqKey="Jianzhu Chen" last="Jianzhu Chen">JIANZHU CHEN</name>
<affiliation><inist:fA14 i1="05"><s1>Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology</s1>
<s2>Cambridge, MA 02139</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yongjun Liu" sort="Yongjun Liu" uniqKey="Yongjun Liu" last="Yongjun Liu">YONGJUN LIU</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Immunology and Center for Cancer Immunology Research, University of Texas, M.D. Anderson Cancer Center</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yongli Yu" sort="Yongli Yu" uniqKey="Yongli Yu" last="Yongli Yu">YONGLI YU</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Immunology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>7 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Liying Wang" sort="Liying Wang" uniqKey="Liying Wang" last="Liying Wang">LIYING WANG</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Molecular Biology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0171874</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0171874 INIST</idno>
<idno type="RBID">Pascal:06-0171874</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000533</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide</title>
<author><name sortKey="Musheng Bao" sort="Musheng Bao" uniqKey="Musheng Bao" last="Musheng Bao">MUSHENG BAO</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Molecular Biology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yi Zhang" sort="Yi Zhang" uniqKey="Yi Zhang" last="Yi Zhang">YI ZHANG</name>
<affiliation><inist:fA14 i1="02"><s1>National Institute for the Control of Pharmaceutical and Biological Products</s1>
<s2>Beijing 100050</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Min Wan" sort="Min Wan" uniqKey="Min Wan" last="Min Wan">MIN WAN</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Molecular Biology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Li Dai" sort="Li Dai" uniqKey="Li Dai" last="Li Dai">LI DAI</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Molecular Biology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Xiaoping Hu" sort="Xiaoping Hu" uniqKey="Xiaoping Hu" last="Xiaoping Hu">XIAOPING HU</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Molecular Biology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Xiuli Wu" sort="Xiuli Wu" uniqKey="Xiuli Wu" last="Xiuli Wu">XIULI WU</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Molecular Biology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Li Wang" sort="Li Wang" uniqKey="Li Wang" last="Li Wang">LI WANG</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Immunology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>7 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ping Deng" sort="Ping Deng" uniqKey="Ping Deng" last="Ping Deng">PING DENG</name>
<affiliation><inist:fA14 i1="04"><s1>The Blood Center of Jilin Province</s1>
<s2>Changchun 130033</s2>
<s3>CHN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Junzhi Wang" sort="Junzhi Wang" uniqKey="Junzhi Wang" last="Junzhi Wang">JUNZHI WANG</name>
<affiliation><inist:fA14 i1="02"><s1>National Institute for the Control of Pharmaceutical and Biological Products</s1>
<s2>Beijing 100050</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jianzhu Chen" sort="Jianzhu Chen" uniqKey="Jianzhu Chen" last="Jianzhu Chen">JIANZHU CHEN</name>
<affiliation><inist:fA14 i1="05"><s1>Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology</s1>
<s2>Cambridge, MA 02139</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yongjun Liu" sort="Yongjun Liu" uniqKey="Yongjun Liu" last="Yongjun Liu">YONGJUN LIU</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Immunology and Center for Cancer Immunology Research, University of Texas, M.D. Anderson Cancer Center</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yongli Yu" sort="Yongli Yu" uniqKey="Yongli Yu" last="Yongli Yu">YONGLI YU</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Immunology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>7 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Liying Wang" sort="Liying Wang" uniqKey="Liying Wang" last="Liying Wang">LIYING WANG</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Molecular Biology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Clinical immunology : (Orlando, Fla. Print)</title>
<title level="j" type="abbreviated">Clin. immunol. : (Orlando, Fla., Print)</title>
<idno type="ISSN">1521-6616</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical immunology : (Orlando, Fla. Print)</title>
<title level="j" type="abbreviated">Clin. immunol. : (Orlando, Fla., Print)</title>
<idno type="ISSN">1521-6616</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>B-Lymphocyte</term>
<term>Coronavirus</term>
<term>GC rich sequence</term>
<term>Gamma interferon</term>
<term>Immunity</term>
<term>Mononuclear cell</term>
<term>Natural killer cell</term>
<term>Nucleotide sequence</term>
<term>Oligodeoxyribonucleotide</term>
<term>Severe acute respiratory syndrome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
<term>Coronavirus</term>
<term>Immunité</term>
<term>Interféron gamma</term>
<term>Séquence riche GC</term>
<term>Séquence nucléotide</term>
<term>Oligodésoxyribonucléotide</term>
<term>Mononucléaire</term>
<term>Lymphocyte B</term>
<term>Cellule NK</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To develop CpG oligodeoxynucleotides (CpG ODNs) based therapy for prevention and treatment of severe acute respiratory syndrome (SARS), we selected a novel CpG ODN (BW001), which displays B-type CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3', and tested for its anti-SARS-CoV activity. We found that the supematants of human PBMCs stimulated by BW001 significantly protected Vero cells from SARS-CoV infection. BW001 could stimulate human PBMCs and pDCs to secrete high level of IFN-α and promote human PBMCs and B cells to proliferate. Furthermore, we demonstrated that BW001 could activate CD19<sup>+</sup>
 B cells and CD56<sup>+</sup>
 NK cells in human PBMCs. In addition, BW001 could enhance NK cytotoxicity and IFN-γ secretion in human PBMCs. Together, BW001 represents a novel type of CpG ODN and may have potential for the development of treatment and prevention for SARS as well as other viral associated diseases.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1521-6616</s0>
</fA01>
<fA02 i1="01"><s0>CLIIFY</s0>
</fA02>
<fA03 i2="1"><s0>Clin. immunol. : (Orlando, Fla., Print)</s0>
</fA03>
<fA05><s2>118</s2>
</fA05>
<fA06><s2>2-3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MUSHENG BAO</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>YI ZHANG</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MIN WAN</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LI DAI</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>XIAOPING HU</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>XIULI WU</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LI WANG</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>PING DENG</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>JUNZHI WANG</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>JIANZHU CHEN</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>YONGJUN LIU</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>YONGLI YU</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>LIYING WANG</s1>
</fA11>
<fA14 i1="01"><s1>Department of Molecular Biology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>National Institute for the Control of Pharmaceutical and Biological Products</s1>
<s2>Beijing 100050</s2>
<s3>CHN</s3>
<sZ>2 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Immunology, College of Basic Medicine, Jilin University</s1>
<s2>Changchun 130021</s2>
<s3>CHN</s3>
<sZ>7 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>The Blood Center of Jilin Province</s1>
<s2>Changchun 130033</s2>
<s3>CHN</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology</s1>
<s2>Cambridge, MA 02139</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Immunology and Center for Cancer Immunology Research, University of Texas, M.D. Anderson Cancer Center</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA20><s1>180-187</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>15461</s2>
<s5>354000153419030080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>29 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0171874</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Clinical immunology : (Orlando, Fla. Print)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>To develop CpG oligodeoxynucleotides (CpG ODNs) based therapy for prevention and treatment of severe acute respiratory syndrome (SARS), we selected a novel CpG ODN (BW001), which displays B-type CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3', and tested for its anti-SARS-CoV activity. We found that the supematants of human PBMCs stimulated by BW001 significantly protected Vero cells from SARS-CoV infection. BW001 could stimulate human PBMCs and pDCs to secrete high level of IFN-α and promote human PBMCs and B cells to proliferate. Furthermore, we demonstrated that BW001 could activate CD19<sup>+</sup>
 B cells and CD56<sup>+</sup>
 NK cells in human PBMCs. In addition, BW001 could enhance NK cytotoxicity and IFN-γ secretion in human PBMCs. Together, BW001 represents a novel type of CpG ODN and may have potential for the development of treatment and prevention for SARS as well as other viral associated diseases.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B06</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Immunité</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Immunity</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Inmunidad</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Interféron gamma</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Gamma interferon</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Interferón gamma</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Séquence riche GC</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>GC rich sequence</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Secuencia rica GC</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Séquence nucléotide</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Nucleotide sequence</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Secuencia nucleótido</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Oligodésoxyribonucléotide</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Oligodeoxyribonucleotide</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Oligodesoxirribonucleótido</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Mononucléaire</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Mononuclear cell</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Mononuclear</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Lymphocyte B</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>B-Lymphocyte</s0>
<s5>12</s5>
<s6>«B»-Lymphocyte</s6>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Linfocito B</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Cellule NK</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Natural killer cell</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Célula NK</s0>
<s5>17</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Immunologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Immunology</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Inmunología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Immunopathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Immunopathology</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Inmunopatología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>107</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0171874 INIST</NO>
<ET>Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide</ET>
<AU>MUSHENG BAO; YI ZHANG; MIN WAN; LI DAI; XIAOPING HU; XIULI WU; LI WANG; PING DENG; JUNZHI WANG; JIANZHU CHEN; YONGJUN LIU; YONGLI YU; LIYING WANG</AU>
<AF>Department of Molecular Biology, College of Basic Medicine, Jilin University/Changchun 130021/Chine (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 13 aut.); National Institute for the Control of Pharmaceutical and Biological Products/Beijing 100050/Chine (2 aut., 9 aut.); Department of Immunology, College of Basic Medicine, Jilin University/Changchun 130021/Chine (7 aut., 12 aut.); The Blood Center of Jilin Province/Changchun 130033/Chine (8 aut.); Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology/Cambridge, MA 02139/Etats-Unis (10 aut.); Department of Immunology and Center for Cancer Immunology Research, University of Texas, M.D. Anderson Cancer Center/Houston, TX 77030/Etats-Unis (11 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Clinical immunology : (Orlando, Fla. Print); ISSN 1521-6616; Coden CLIIFY; Etats-Unis; Da. 2006; Vol. 118; No. 2-3; Pp. 180-187; Bibl. 29 ref.</SO>
<LA>Anglais</LA>
<EA>To develop CpG oligodeoxynucleotides (CpG ODNs) based therapy for prevention and treatment of severe acute respiratory syndrome (SARS), we selected a novel CpG ODN (BW001), which displays B-type CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3', and tested for its anti-SARS-CoV activity. We found that the supematants of human PBMCs stimulated by BW001 significantly protected Vero cells from SARS-CoV infection. BW001 could stimulate human PBMCs and pDCs to secrete high level of IFN-α and promote human PBMCs and B cells to proliferate. Furthermore, we demonstrated that BW001 could activate CD19<sup>+</sup>
 B cells and CD56<sup>+</sup>
 NK cells in human PBMCs. In addition, BW001 could enhance NK cytotoxicity and IFN-γ secretion in human PBMCs. Together, BW001 represents a novel type of CpG ODN and may have potential for the development of treatment and prevention for SARS as well as other viral associated diseases.</EA>
<CC>002B06; 002A06</CC>
<FD>Syndrome respiratoire aigu sévère; Coronavirus; Immunité; Interféron gamma; Séquence riche GC; Séquence nucléotide; Oligodésoxyribonucléotide; Mononucléaire; Lymphocyte B; Cellule NK</FD>
<FG>Virose; Infection; Coronaviridae; Nidovirales; Virus; Immunologie; Immunopathologie; Appareil respiratoire pathologie; Poumon pathologie</FG>
<ED>Severe acute respiratory syndrome; Coronavirus; Immunity; Gamma interferon; GC rich sequence; Nucleotide sequence; Oligodeoxyribonucleotide; Mononuclear cell; B-Lymphocyte; Natural killer cell</ED>
<EG>Viral disease; Infection; Coronaviridae; Nidovirales; Virus; Immunology; Immunopathology; Respiratory disease; Lung disease</EG>
<SD>Síndrome respiratorio agudo severo; Coronavirus; Inmunidad; Interferón gamma; Secuencia rica GC; Secuencia nucleótido; Oligodesoxirribonucleótido; Mononuclear; Linfocito B; Célula NK</SD>
<LO>INIST-15461.354000153419030080</LO>
<ID>06-0171874</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000533 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000533 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0171874
   |texte=   Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide

Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri